DEC 13, 2018 9:00 AM PST

Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance

Speaker

Abstract
DATE:   December 13, 2018
TIME:    09:00am PST, 12:00pm EST
 
Breast cancers are classified into three main subtypes according to their receptor status: estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), and triple negative. These classifications provide information about the biology of the disease and help clinicians determine which treatments to use for patients. Targeted therapy for HER2+ breast cancer, including trastuzamab and pertuzamab, and for ER+ breast cancer, including Tamoxifen and aromatase inhibitors, have drastically improved survival outcomes for patients with these disease subtypes. However, when tumors are both HER2+ and ER+, treatment decisions and outcomes are less clear. HER2+/ER+ breast cancers treated with HER2 targeted therapies do not respond as well as HER2+/ER-negative tumors. Our lab is interested in understanding the biology behind these differences in response as well as better defining treatment options for HER2+/ER+ breast cancer. We have established long-term estrogen deprived (LTED) cell models of HER2+/ER+ breast cancer utilizing phenol-red free media as a surrogate for aromatase inhibitor treatment and Fulvestrant (a selective estrogen receptor degrader) resistant cell lines using increasing doses of Fulvestrant over time. We are testing combination therapy over different time courses then measure proliferation and targets of downstream signaling including protein phosphorylation by western blot and gene transcription by qRTPCR. Ultimately, these results will help inform clinicians about the most effective treatment for patients with HER2+/ER+ breast cancer.
 
Learning Objectives:
  • Understand how scientists use cell culture to model endocrine resistance in breast cancer
  • Decipher differences between breast cancer subtypes and treatment options
  • Describe changes in signaling pathways that occur during endocrine resistance 

Show Resources
DEC 13, 2018 9:00 AM PST

Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance


Specialty

Cancer Research

Molecular Biology

Cell Biology

Clinical Diagnostics

Immunology

Biotechnology

Genetics

Cancer Diagnostics

Cancer Therapeutics

Clinical Research

Medicine

Molecular Diagnostics

Laboratory Testing

Biomarkers

Biochemistry

Geography

North America66%

Europe15%

Asia12%

Africa4%

South America3%

Registration Source

Website Visitors54%

Email Promotions31%

WAVE Newsletter Promotion4%

Social Media Promotions2%

Other7%

Job Title

Medical Laboratory Technician20%

Student13%

Research Scientist11%

Executive9%

Medical Doctor/Specialist8%

Clinical Laboratory Scientist7%

Educator/Faculty6%

Scientist5%

Lab Management5%

Facility/Department Manager5%

Post Doc3%

QC/QA2%

Chemist2%

Consultant2%

Veterinarian1%

Pharmacist1%

Organization

Academic Institution20%

Hospital18%

Clinical Laboratory15%

Research Institute6%

Biotech Company6%

Medical Center5%

Government4%

Pharmaceutical Company3%

Life Science Company3%

Medical School3%

Non-Profit Organization2%

Medical Device Company2%

Consultant1%

Ambulatory Care1%

Other2%


Show Resources
Show Resources
Connect with us